Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1 1

Status

Completed 3Recruiting 1

Sponsor Class

OTHER 7INDUSTRY 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 4Lymphoid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25Leukemia, Myeloid, Chronic-Phase 14Leukemia 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Recurrence 4Breast Neoplasms 4Blast Crisis 4Prostatic Neoplasms 3Neoplasms 3Bronchiolitis Obliterans Syndrome 3Neoplasm Metastasis 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Advanced Breast Cancer 2Philadelphia Chromosome 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Indications Cancer 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancer 1

Interventions

nilotinib 4Imatinib Mesylate 4Dasatinib 4troxacitabine 1ponatinib 1litronesib 1exatecan 1carfilzomib 1bosutinib 1blinatumomab 1asciminib 1TAK-901 1STA 9090 1Panobinostat 1Homoharringtonine 1Fentanyl 1Dexamethasone 1Decitabine 1Calcium Dobesilate 12-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Blast Crisis × Dasatinib × Clear all
NCT04877522 2026-06-10

Asciminib Roll-over Study

Novartis

Phase 4 Recruiting
347 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00103701 2011-04-14

BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia

Bristol-Myers Squibb

Phase 1 Completed
LymphoidMyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00101816 2010-08-10

Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

Bristol-Myers Squibb

Phase 2 Completed
124 enrolled 28 charts
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00298987 2010-02-08

A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate

Bristol-Myers Squibb

Phase 2 Completed
400 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡